AI Product

Recursion OS

Recursion OS platform combining automated experimentation, proprietary biological and chemical datasets, and AI models to discover and advance clinical-stage drug…

Intelligence Summary

Product
  • Active
  • Verified public sources
  • Developer Recursion Pharmaceuticals
  • Category Biotechnology
  • Status Active
  • Latest update 2013: Recursion Pharmaceuticals founded in Salt Lake City; Chris Gibson co-founded the company from University of Utah research.
  • Documentation Official page
  • Last reviewed Jul 2026
6 Technologies

Official product page

Target customer

Internal pipeline development, pharmaceutical partners seeking AI-enabled discovery collaborations, and investors evaluating clinical validation of AI drug discovery platforms.

Features & capabilities

Industries: AI in Healthcare; Biotechnology

Related reports

Related insights

Overview

Recursion OS platform combining automated experimentation, proprietary biological and chemical datasets, and AI models to discover and advance clinical-stage drug candidates across oncology, rare disease, and other therapeutic areas.

Product and company

Recursion OS is a verified product offering linked to the Brel Digital company profile for Recursion Pharmaceuticals.

Use cases

Recursion OS platform combining automated experimentation, proprietary biological and chemical datasets, and AI models to discover and advance clinical-stage drug candidates across oncology, rare disease, and other therapeutic areas.

Target customer

Internal pipeline development, pharmaceutical partners seeking AI-enabled discovery collaborations, and investors evaluating clinical validation of AI drug discovery platforms.

Technologies

Primary technologies assigned from the linked company profile: Clinical Documentation, Deep Learning, Healthcare Analytics, Machine Learning, Predictive Analytics, Vector Database.

Sources and references

  • Official product / company source: https://ir.recursion.com/news-releases/news-release-details/positive-phase-1b2-results-ongoing-rec-4881-tupelo-trial-0
  • Supporting source: https://ir.recursion.com/governance/board-of-directors

Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.

Last reviewed

This product profile was last reviewed on 2026-07-14.

Correction request

If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.

Features and capabilities

  • Recursion OS platform combining automated experimentation, proprietary biological and chemical datasets, and AI models to
  • automated experimentation
  • proprietary biological
  • chemical datasets
  • and AI models to discover
  • advance clinical-stage drug candidates across oncology
  • rare disease
  • and other therapeutic areas

Extracted from the linked company product description already verified on Brel. No capabilities were invented.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Enquire about this product profile

Messages are delivered to contact@breldigital.com.